Continuing our efforts in developing potent α 1 -adrenoceptor antagonists with uroselective profile, a series of derivatives of pyrrolidines was biologically evaluated in vitro for their affinity for α 1 - and α 2 -adrenoceptors. Result from binding assays allowed the identification of compounds with the highest affinity and selectivity for α 1 -adrenoceptors behaving as potent antagonists at those sites in cellular functional assays. Among tested derivatives, compound V [1-(3-(4-(3- chlorophenyl)piperazin-1-yl)propyl)pyrrolidin-2-one], displayed a 152-fold functional preference to α 1A -adrenoceptor versus α 1B subtype. Finally, the most promising compound V at the doses of 2, 5 and 10 mg/kg after i.v. administered, in contrast to tamsulosin (at a dose of 2 mg/kg, i.v.) did not significantly decrease systolic and diastolic blood pressure in normotensive anesthetized rats. This selected α 1A -adrenoceptor antagonist with stronger uroselective profile, requires further research.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.